Hilton Head Capital Partners LLC Makes New Investment in SiBone $SIBN

Hilton Head Capital Partners LLC acquired a new position in SiBone (NASDAQ:SIBN) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 38,019 shares of the company’s stock, valued at approximately $750,000. Hilton Head Capital Partners LLC owned 0.09% of SiBone as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. ANTIPODES PARTNERS Ltd acquired a new position in SiBone in the 4th quarter worth approximately $29,000. State of Wyoming acquired a new position in SiBone in the 2nd quarter worth approximately $55,000. Canada Pension Plan Investment Board acquired a new position in SiBone in the 2nd quarter worth approximately $68,000. Larson Financial Group LLC boosted its stake in SiBone by 42.3% in the 4th quarter. Larson Financial Group LLC now owns 3,569 shares of the company’s stock worth $70,000 after purchasing an additional 1,061 shares during the period. Finally, Quarry LP boosted its stake in SiBone by 862.6% in the 3rd quarter. Quarry LP now owns 4,861 shares of the company’s stock worth $72,000 after purchasing an additional 4,356 shares during the period. Institutional investors and hedge funds own 98.11% of the company’s stock.

Insider Transactions at SiBone

In other news, CEO Laura Francis sold 14,957 shares of the business’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $14.71, for a total transaction of $220,017.47. Following the transaction, the chief executive officer owned 503,444 shares in the company, valued at approximately $7,405,661.24. The trade was a 2.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Anshul Maheshwari sold 3,318 shares of the business’s stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $12.87, for a total transaction of $42,702.66. Following the transaction, the chief financial officer owned 263,148 shares in the company, valued at approximately $3,386,714.76. The trade was a 1.25% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 36,852 shares of company stock worth $523,018. Corporate insiders own 4.00% of the company’s stock.

SiBone Stock Performance

Shares of SIBN opened at $15.12 on Monday. The company has a market capitalization of $670.56 million, a PE ratio of -38.77 and a beta of 0.70. SiBone has a one year low of $11.48 and a one year high of $21.89. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.99 and a quick ratio of 8.34. The company’s fifty day moving average price is $13.68 and its 200 day moving average price is $15.94.

SiBone (NASDAQ:SIBN) last announced its earnings results on Monday, May 11th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.07. The firm had revenue of $52.59 million for the quarter, compared to the consensus estimate of $51.16 million. SiBone had a negative net margin of 8.10% and a negative return on equity of 9.56%. As a group, analysts expect that SiBone will post -0.44 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Truist Financial reaffirmed a “buy” rating and issued a $18.00 price objective (down from $20.00) on shares of SiBone in a research note on Tuesday, May 12th. TD Cowen decreased their price objective on shares of SiBone from $22.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. Finally, Wall Street Zen lowered shares of SiBone from a “buy” rating to a “hold” rating in a research note on Saturday, April 18th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $23.00.

About SiBone

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.